key: cord-0716365-9ua245rz
authors: Zhu, Jingen; Ananthaswamy, Neeti; Jain, Swati; Batra, Himanshu; Tang, Wei-Chun; Lewry, Douglass A.; Richards, Michael L.; David, Sunil A.; Kilgore, Paul B.; Sha, Jian; Drelich, Aleksandra; Tseng, Chien-Te K.; Chopra, Ashok K.; Rao, Venigalla B.
title: A Universal Bacteriophage T4 Nanoparticle Platform to Design Multiplex SARS-CoV-2 Vaccine Candidates by CRISPR Engineering
date: 2021-01-20
journal: bioRxiv
DOI: 10.1101/2021.01.19.427310
sha: 231f8e72dd77203b0104d2ab1bde83b13741eb05
doc_id: 716365
cord_uid: 9ua245rz

A “universal” vaccine design platform that can rapidly generate multiplex vaccine candidates is critically needed to control future pandemics. Here, using SARS-CoV-2 pandemic virus as a model, we have developed such a platform by CRISPR engineering of bacteriophage T4. A pipeline of vaccine candidates were engineered by incorporating various viral components into appropriate compartments of phage nanoparticle structure. These include: expressible spike genes in genome, spike and envelope epitopes as surface decorations, and nucleocapsid proteins in packaged core. Phage decorated with spike trimers is found to be the most potent vaccine candidate in mouse and rabbit models. Without any adjuvant, this vaccine stimulated robust immune responses, both TH1 and TH2 IgG subclasses, blocked virus-receptor interactions, neutralized viral infection, and conferred complete protection against viral challenge. This new type of nanovaccine design framework might allow rapid deployment of effective phage-based vaccines against any emerging pathogen in the future.

A "universal" vaccine design platform that can rapidly generate multiplex vaccine candidates is 24 critically needed to control future pandemics. Here, using SARS-CoV-2 pandemic virus as a 25 model, we have developed such a platform by CRISPR engineering of bacteriophage T4. A 26 pipeline of vaccine candidates were engineered by incorporating various viral components into 27 appropriate compartments of phage nanoparticle structure. These include: expressible spike 28 genes in genome, spike and envelope epitopes as surface decorations, and nucleocapsid 29 proteins in packaged core. Phage decorated with spike trimers is found to be the most potent Rapid discovery of safe and effective vaccines against emerging and pandemic pathogens 46 such as the novel coronavirus SARS-CoV-2 1, 2 requires a "universal" vaccine design platform that 47

can be adapted to any infectious agent 3, 4 . It should allow incorporation of diverse targets, DNAs, 48 and proteins (multicomponent), full-length proteins as well as peptides and domains, in various 49 combinations (multivalent). Such a multiplex platform would not only compress the timeline for 50 vaccine discovery but also offers critical choices for selecting the most effective vaccine 51 candidate(s) without going through iterative design cycles 4-6 . 52

Numerous SARS-CoV-2 vaccine candidates have been developed at record-breaking 53 pace to quell this devastating pandemic and many are in clinical trials 5, 7-11 . Two of these, both 54 mRNA based, have been approved by FDA for emergency use authorization. However, innovative 55 platforms are still desperately needed because future pathogens might be more complex and their 56 vaccine targets may not be as well-defined 3, 4, 11 . A drawback of the current platforms is that they 57 are largely limited to a single vaccine target. They also lack sufficient engineering flexibility to 58 generate multiplex vaccines, require strong chemical adjuvants to boost immune responses, and 59 may not be accessible to resource-poor countries 4-6, 12 . Here, we present a "universal" 60 nanovaccine platform by CRISPR engineering of bacteriophage (phage) T4 that can rapidly 61 generate multiplex vaccine candidates against any emerging pathogen during epidemic or 62 pandemic situations. 63

Tailed bacteriophages such as T4 are the most abundant and widely distributed organisms 64 on Earth. T4 belongs to myoviridae family, infects Escherichia coli, and has served as an 65 extraordinary model organism in molecular biology and biotechnology 13 . It consists of a 1200 Å 66 long and 860 Å wide prolate head (or capsid) that encapsidates ~170 kb linear DNA genome, and 67 a ~1400 Å long contractile tail with six long tail fibers emanating from a baseplate present at the 68 tip of the tail 14 (Figure 1 ). The head, the principal component for vaccine design, is assembled 69 unprecedented engineering power and flexibility of this approach. When tested in mouse and 96 rabbit models, one of the candidates, T4 phage decorated with S-trimers (Figure 1e-g; Video) 97 elicited robust immunogenicity and ACE-2 (angiotensin converting enzyme-2) receptor 34 blocking 98 and virus neutralizing antibodies that conferred complete protection against virus challenge in a 99 mouse model. 100

Our studies thus established a "blueprint" for a new type of nanovaccine framework for 101 rapid and multiplex design of effective vaccine candidates that can potentially be applied to any 102 emerging pathogen in the future. CoV-2 inserts were then generated by simple phage infections and identifying the recombinant 110 phages in the progeny (c). For example, recombinant phage containing CoV-2 insert #1 (dark 111 blue) can be used to infect CRISPR E. coli containing Co-V2 insert containing donor plasmid #2 112

(dark red). The progeny plaques obtained will contain recombinant phage #3 with both inserts #1 113 and #2 (dark blue plus dark red) in the same genome. This process was repeated to rapidly 114 construct a pipeline of multiplex T4-SARS-CoV-2 vaccine phages (d). Selected vaccine 115

candidates were then screened in a mouse model (e) to identify the most potent vaccine (f). 116 Structural model of T4-SARS-CoV-2 Nanovaccine showing an enlarged view of a single 117 hexameric capsomer (g). The capsomer shows six subunits of major capsid protein gp23* (green), 118

trimers of Soc (blue), and a Hoc fiber (yellow) at the center of capsomer. The expressible spike 119

genes are inserted into phage genome, the 12 aa E external peptide (red) is displayed at the tip 120

of Hoc fiber, S-trimers (cyan) are attached to Soc subunits, and nucleocapsid proteins (yellow) 121

are packaged in genome core. See Results, Materials and Methods, and Supplementary Video 122 for additional details. 123 124

A series of CRISPR-E. coli strains were constructed by inserting SARS-CoV-2 gene 127 segments into T4 phage genome. Each strain harbored two plasmids (Fig. 2a) ; a "spacer" plasmid 128 expressing the genome-editing nuclease, either type II Cas9 or type V Cpf1, and CRISPR RNAs 129 (crRNAs or "spacer" RNAs) corresponding to target protospacer sequence(s) in phage genome, 130 and a second "donor" plasmid containing the SARS-CoV-2 sequence. The latter also has ~500 131 bp homologous flanking arms of phage genome corresponding to the point of insertion. Four 132 nonessential regions of the genome were chosen for insertion of various SARS-CoV-2 genes (Fig.  133 2b, I-IV). When these E. coli were infected by T4, a double-stranded break would occur in the 134 protospacer sequence by Cas9 or Cpf1 that inactivates the phage genome and no phage should 135 be produced. However, the highly recombinogenic T4 phage allows efficient recombination 136 between the cleaved DNA and the donor plasmid through the flanking homologous arms, 137 transferring the CoV-2 gene into phage genome and propagating it as part of phage infection (Fig.  138 2a). The same strategy was used to introduce many other genetic modifications including 139 deletions by simply creating that modification in the donor plasmid and various modifications were 140 combined as desired by simple phage infections of appropriate CRISPR E. coli (Fig. 1) . 141

Initially, we constructed "acceptor" phages by deleting certain known nonessential segments 142 of the phage genome 35 ; ~18 kb FarP, ~11-kb 39-56, or both (~29 kb), that created space for CoV-143 . We incorporated NP into the T4 nanoparticle by designing a CRISPR strategy that packaged 196 NP molecules inside phage capsid along with the genome. As NP is a nucleic acid binding protein, 197 the packaged phage genome might provide an appropriate environment to localize this protein 37 . 198 During T4 phage morphogenesis, the major capsid protein gp23 assembles around a 199 scaffolding core formed by a cluster of proteins including three nonessential, highly basic, internal 200 proteins IPI, IPII, and IPIII. Following assembly, while most of the scaffold proteins are degraded 201 and expelled from capsid ( Fig. 3a) , the IPs are cleaved only once, next to a ~10 aa N-terminal 202 capsid targeting sequence (CTS; MKTYQEFIAE). The cleaved CTS leaves the capsid but ~1,000 203 molecules of IPs, or any foreign protein fused to CTS, remain in the "expanded" capsid 38 (Fig. 3a) . 204

To replace IPs with NP, we first created an IPIII deletion phage using appropriate spacer and 205 donor ( Supplementary Fig. 2a, Fig. 3b ). Then, a CTS-NP fusion sequence was transferred into 206 this phage under the control of the native IPIII promoter ( Supplementary Fig. 2a ). Next, IPII was 207 deleted to reduce protein packaging competition and increase the copy number of NP 208 ( Supplementary Fig. 2a, Fig. 3b 

Next, we incorporated SARS-CoV-2 antigens onto the nanoparticle surface. We first 255 deleted Hoc and Soc genes from the above recombinant phages and then inserted Hoc-and Soc-256 fused CoV-2 genes under the control of their respective native promoters. Upon infection, these 257 phages would express and assemble the epitopes on T4 capsid surface ( Supplementary Fig. 2e , 258 Fig. 3d ,e). We fused the gene segments corresponding to the N-terminal 12-aa "external domain" 259 peptide (Ee) or the 18-aa peptide from the C-terminal domain (Ec) of E protein to the N-terminus 260 of Hoc (Fig. 3d) . These peptides are predicted to be exposed on the SARS-CoV-2 virion and 261

shown to elicit T cell immune responses in humans 32 . By virtue of fusion to N-terminus of Hoc, 262 these epitopes would be exposed at the tip of ~170 Å-long Hoc fiber 19 . The Ee and Ec recombinant 263 phages indeed showed an upward shift of the Hoc band upon SDS-PAGE ( Fig. 3f ; yellow and 264 magenta arrows). However, only the 12-aa Ee peptide was displayed at the maximum copy 265 number, up to ~155 copies per capsid, while the 18-aa Ec peptide showed lower epitope copies 266 and also affected phage yield (Fig. 3f) . 267

268

We used a similar strategy to display CoV-2 receptor binding domain (RBD) 34 on the capsid 270 surface as a Soc-fusion ( Supplementary Fig. 3a,b) . However, the copy number of the displayed 271 infection. Indeed, phage isolated from these infections showed improved display, ~100 copies of 281 Second, we deployed the well-established Spytag-SpyCatcher technology 39 to display RBD 283 on T4 phage. The optimized SpyCatcher and Spytag from Streptococcus pyogenes, interact 284 with >picomole affinity (approaching "infinite" affinity; second-order rate constant: 5.5 × 10 5 M −1 285 s −1 ) and exquisite specificity that then leads to covalent linkage 39 . To display RBD, phage 286 decorated with the 12.6-kDa soluble SpyCatcher was produced by growing the T4-Spike-Ee-NP-287

SocΔ phage on E. coli expressing Soc-SpyCatcher fusion protein from the T7 expression plasmid 288 ( Supplementary Fig. 3f, Fig. 3g ). Phage prepared from these infections contained up to ~600 289 copies of Soc-SpyCatcher per capsid (Fig. 3i) . 290

Third, RBD was expressed as SUMO-RBD-Spytag fusion protein in E. coli. The SUMO 291 domain is expected to enhance the solubility of RBD 40 , but resulted in only a small improvement 292 ( Supplementary Fig. 3g ). Therefore, the SUMO-RBD-Spytag protein was purified from insoluble 293 inclusion bodies by urea denaturation and refolding (rRBD), and was displayed in vitro on the 294

SpyCatcher phage (Fig. 3j ). SDS-PAGE and WB of the phage particles showed that the SUMO-295 RBD-Spytag was efficiently captured by the SpyCatcher phage as shown by the disappearance 296 of the SpyCatcher band and appearance of higher molecular weight band(s) (Fig. 3k ). The copy 297 number was ~300 rRBD molecules per capsid (Fig. 3k) . 298

The sRBD and rRBD phages produced as above (T4-Spike-Ee-CTSam-NP-sRBD and T4-299

Spike-Ee-CTSam-NP-rRBD) bound to human ACE2 receptor protein 34 (Fig 3l, Supplementary Fig.  300 5a), and to some of the RBD-specific monoclonal antibodies (mAbs) and polyclonal antibodies 301 (pAbs) but not to all ( Fig. 3m to 3o, Supplementary Fig. 5b to 5d). However, these RBDs exhibited 302

considerably lower binding when compared to mammalian-expressed RBD suggesting that the E. 303 coli-produced RBDs were not properly folded (Fig. 3p) . This was also consistent with the co-304 purification of a 65-kDa E. coli GroEL chaperone with RBD indicating the presence of partially 305 folded and/or misfolded RBD ( Supplementary Fig. 3e) . binding to mAb1 and mAb2 than the E. coli rRBD, while binding to pAbs was similar. 339 340

Next, we displayed spike ectodomain (S-ecto) trimers (S-trimer) (433.5 kDa) 31 on T4-342

Spike-Ee-NP-SocΔ phage. The pre-fusion stabilized hexa-Pro S-ectodomain construct described 343 as above 31 was fused to a 16-aa spytag at the C-terminus and expressed in ExpiCHO cells. The 344 ectodomain trimers secreted into the culture medium were purified by HisTrap affinity 345 chromatography and size-exclusion chromatography ( Supplementary Fig. 6a,b) . These trimers 346 appeared authentic and native-like because: i) they migrated predominantly as a single species 347 and showed no nonspecific aggregation, which usually appears as a peak (or shoulder) near void 348 volume and as a smeary high molecular weight species on native gel ( Supplementary Fig. 6a,b) , 349

and ii) they bound efficiently to human ACE2 receptor ( Supplementary Fig. 6c ) and to 350 conformation-specific RBD mAbs ( Supplementary Fig. 5e ). Importantly, the S-trimers were 351 efficiently captured by the SpyCatcher phage produced as above. Binding was so strong that 352 efficient assembly occurred by simple mixing of trimers and phage even at an equimolar ratio of 353 S-trimers to T4-spycatcher molecules (Fig. 4a,b) . The copy number was ~100 S-trimers per phage 354 capsid (Fig. 4b) . Cryo-EM showed decoration of T4 phage capsids with S-trimers (Fig. 4c) , 355 mimicking the orientation of spikes on SARS-CoV-2 virion 41 . The trimer-decorated T4 phage 356 efficiently bound to human ACE2 receptor (Fig. 4d, Supplementary Fig. 7a ) and when co-357 displayed with GFP, it decorated the ACE2-expressing HEK293 cells (Fig. 4e, Supplementary Fig.  358 7b, c). showing the decoration of phage T4 nanoparticles with spike ectodomain trimers via Spytag-363

SpyCatcher bridges. b. In vitro assembly of S-trimers on T4-SpyCatcher phage at increasing 364 ratios of S-trimer molecules to Soc binding sites (0:1 to 4:1). Phage and S-trimer were incubated 365 at 4°C for 1 hr, followed by centrifugation to remove the unbound material. After two washes, the 366 pellet was re-suspended in buffer and SDS-PAGE was performed. c. Representative cryo-EM 367

images showing T4-SocΔ, T4-(Soc-SpyCatcher), and T4-(Soc-SpyCatcher)-S-trimers phages. 368

The red arrowhead indicates the representative S-trimer displayed on phage. Bar = 100 nm. d.

ELISA analysis of T4-S-trimer phage binding to ACE2 at various ACE2 concentrations. ****P < trimers. T4-S-trimer particles and ACE2 were incubated at equimolar ratio for 1 hr at 4°C, followed 389 by high speed centrifugation. After two washes, the pellet was re-suspended in buffer and SDS-390 PAGE was performed. Presence of ACE2 in the pellet was found with these phage particles but 391 not with the control phage lacking S-trimers. b. Immunofluorescence assay showing expression 392 of ACE2 on 293 cells. Two days after ACE2 plasmid transfection, HEK293 cells were incubated 393 with RBD, followed by anti-RBD antibody and Rhodamine-conjugated second antibody. c. Lack 394 of binding of T4-GFP control phage (without S-trimers) to ACE2-293 cells. No difference in 395 fluorescence was observed. The nuclei were stained with Hoechst. T4* indicates T4-(S-ecto)-396

RBD-NP-Ee-SocΔ. 397 398

The T4-CoV-2 vaccine candidates generated as above by sequential engineering 400 ( Supplementary Fig. 8a,b) were screened for their immunogenicity and protective efficacy in a 401 mouse model. BALB/c mice were immunized at weeks 0, 3, and 6 with CsCl-purified phage 402 particles (Fig. 5a,b ) and sera were analyzed by a series of immunological assays. 403 SARS-CoV-2-specific antibody titers were determined by ELISA using purified proteins (S-404 ecto, RBD, NP, or E) as coating antigens. Recombinant phages that delivered CoV-2 DNA alone 405 did not induce significant titers of spike protein-specific antibodies (Fig. 5c,d, Supplementary Fig.  406 9a to 9d). However, when the same were boosted once with phage nanoparticles displayed with 407 S-trimers, significant antibody titers were elicited ( Supplementary Fig. 10a) . 408

Without any adjuvant, the T4 nanoparticles stimulated strong antibody titers to phage-409 delivered proteins/peptides, either displayed on surface or packaged inside. These include RBD-410 and spike-specific antibodies, E-specific antibodies, and NP-specific antibodies (Fig. 5c to 5f ). 411

However, the highest titers, up to an endpoint titer of ~1.5 x 10 6 , were obtained with phage 412 nanoparticles decorated with S-trimers ( Fig. 5c to 5f ). Most of these antibodies are RBD-specific 413 since no significant difference was observed between the endpoint titers obtained by using either 414 RBD or S-trimers as the coating antigen (Fig 5c,d) . This result is consistent with recent reports 415 that the immunodominant RBD comprises multiple distinct antigenic sites and is the target of most 416 neutralizing activity in COVID-19 convalescent sera 42, 43 . 417

Furthermore, the antibodies elicited were conformation-specific. For instance, the antibodies 418 elicited against sRBD or rRBD displayed on phage reacted poorly with the mammalian-expressed 419 S-trimer or RBD (Fig 5c,d) , consistent with the antigenicity data described above that these also 420 reacted poorly with ACE2 and conformation-specific mAbs (Fig. 3p, Supplementary Fig. 5e ). 421

Similarly, the antibodies elicited against T4-dispalyed S-trimers reacted poorly with the E.coli-422 produced RBD (end point titer of ~10 2 using E. coli RBD as the coating antigen vs ~10 5 using 423 mammalian RBD) ( Supplementary Fig. 10d) . 424

The spike-specific titers elicited by phage-decorated trimers without any adjuvant were as 425 high as those generated with Alhydrogel adjuvant (Fig. 5c,d,g) . Furthermore, notably, IgG 426 subclass data indicated that phage nanoparticles stimulated both humoral (TH2) and cellular (TH1) 427 arms of the immune system. In mice, IgG2a subclass represents TH1 response whereas IgG1 428 class reflects TH2 response. The adjuvant-free T4 nanoparticles mounted high levels of both IgG1 429 and IgG2a classes against all three SARS-CoV-2 antigens; spike/RBD, E, and NP, whereas the 430 Alhydrogel-adjuvanted trimers predominantly elicited TH2-derived IgG1 class antibodies (Fig. 5h,  431 Supplementary Fig. 9a to 9j) . In fact, the TH1-derived IgG2a antibodies were higher than the TH2 432 derived IgG1 antibodies in T4 groups, whereas the Alhydrogel-adjuvanted mice induced ≥2 orders 433 of magnitude lower IgG2a antibodies (Fig. 5h, Supplementary Fig. 9i,j) . While TH2-biased 434 responses may lead to lung injury via eosinophilic infiltrates, the TH1-type responses are proposed 435 to alleviate potential lung immunopathology and reduce the potential for disease enhancement 44, 436 45 . The T4 nanoparticle vaccine with a balanced TH1 and TH2 responses might therefore be 437 optimal for safety and virus clearance. This point however requires further investigation. 438

The T4-stimulated spike-specific antibodies blocked binding of RBD to human ACE-2 439 expressed on HEK293 cells in a dose-dependent manner (Fig. 5i, Supplementary Fig. 9k) . 440

Importantly, these antibodies also exhibited strong virus neutralizing activity as determined by 441

Vero E6 cell cytopathic assay using the live BSL-3 SARS-CoV-2 US-WA-1/2020 strain, the first 442 patient isolate obtained through the CDC 46 (Fig. 5j) . The neutralization titers correlated well with 443 protective efficacy when mice were challenged with mouse-adapted BSL-3 SARS-CoV-2 MA10 444 virus 47 (Fig. 5k,l) . 445

Upon challenge, the naï ve and T4 control mice showed rapid decline in weight, up to 25% 446 of their starting weight in five days due to acute viral infection, and were moribund (humanely 447 euthanized) or succumbed to infection. After day 5, the surviving mice began to re-gain weight 448 and recovery from infection during the next several days (Fig. 5k,l) . This rapid weight loss resulted 449 in ~80% mortality rate in the control animals (Fig. 5k,l) . None of the groups receiving the spike 450 DNA vaccine alone and/or CoV-2 antigens other than spike trimers showed significant protection, 451 closely correlating to the lack or extremely weak neutralization antibody responses. However, E. 452 coli RBD groups (G6 and G7) showed less weight loss and higher survival rate than the 453 susceptible control groups (G3 and G4) (Fig. 5k,l) . On the other hand, mice vaccinated with T4-454 decorated trimers exhibited profound neutralization antibody responses and were fully protected 455 from the acute onset of morbidity (weight loss and other signs of illness) and mortality. The weight 456 loss, if any, was insignificant for both these groups, as well as the positive control group 457 vaccinated with Alhydrogel-adjuvanted trimers (Fig. 5k,l) . Additionally, those mice boosted with 458 one dose of T4-trimers also showed partial protection. The weight loss was in between 459 unprotected and protected groups, with a milder weight loss than the unimmunized and 460 challenged controls, clearly correlating protection with spike-specific antibodies (Supplementary 461 Fig. 10b,c) . 462

Next, we evaluated the most effective T4 phage-decorated S-trimers vaccine in a second 463 animal model, the New Zealand White rabbit (Fig. 6a ). This vaccine, again without any adjuvant, 464 by just two immunizations at days 0 and 15, elicited robust spike-and RBD-specific antibodies 465 and virus neutralization titers in rabbits that are ~5-6 times greater than those obtained in mice, 466 ( Fig. 6b to 6d, Supplementary Fig. 11) . Likewise, inclusion of displayed Ee peptide and packaged 467 NP into the nanoparticle broadened the immune responses (Fig. 6e,f) while addition of a TH1-468 biased adjuvant Alhydroxyquim-II only slightly enhanced the antibody titers ( Fig. 6b to 6d) . 469

Together, these datasets allowed selection of a highly effective T4 phage vaccine candidate 470 that generated robust virus neutralization titers in two different animal models, mouse and rabbit, 471 and conferred complete protection against acute viral infection in mice. 472 showed maximum weight loss in control groups. In groups G3 and G4, only 20% of mice survived 500 after day 5. Thus, data presented after day 5 are biased toward minor survivors. The data were 501

presented as means ± SD. l. Survival rate of mice against SARS-CoV-2 MA10 challenge. The resultant T4-mutant 1 (T4-M1) was used to infect bacteria containing spacer 2 and donor 2 508

to produce recombinant T4-mutant 2 (T4-M2) which has two insertion/deletion mutations, and so 509

forth. By sequential CRISPR engineering and simple phage infections, recombinant phages with 510 multiple desired mutations were created. Each color on phage capsid here represents a mutation. 511 b. One example of sequential phage CRISPR engineering for creating the T4-SARS-CoV-2 512

nanovaccine. Numerous CoV-2 components, including CAGpromoter-S-ecto insertion, 513

CAGpromoter-S-fl insertion, CMVpromoter-RBD insertion, Hoc deletion, Ee-Hoc insertion, Ec-514

Hoc insertion, Soc deletion, Soc-sRBD display, M21-Soc-sRBD display, Soc-SpyCatcher display, 515 refolding SUMO-RBD-Spy display, S-trimer display, IPIII deletion, IPII deletion, and NP 516 encapsidation, were permutated and combined as needed. The resultant SARS-CoV-2 vaccine 517 candidates were characterized by PCR, DNA sequencing and/or SDS-PAGE, and some of these 518

were then tested in a mouse study. M21 indicates a potential T cell 21 aa epitope 519 (SYFIASFRLFARTRSMWSFNP) from SARS-CoV-2 membrane protein. c. WB showing NP 520 protein encapsidation in the phages containing CTSam-NP insertion at IPIII deletion site. Anti-E IgG1 (g) and IgG2a (h) antibody titers in the boost-2 sera. *P < 0.05, **P < 0.01, ***P < 528 0.001, and ****P < 0.0001, compared with phage control group G3. ns, no significance, P > 0.05. 529 ND, not detected. i and j. Anti-S-ecto IgG1 (i) and IgG2a (j) antibody titers in the sera from S-530

trimer & Alhydrogel (G2) group and T4-S-trimer (G8 and G9) groups at 2 weeks (prime), 5 weeks 531

(boost-1), and 8 weeks (boost-2). **P < 0.01 and ****P < 0.01. k. Blocking of native RBD protein 532

binding to HEK293-ACE2 by 2500-fold diluted sera. Sera from phage control group (G3), S-533 trimers-Alhydrogel group (G2), and T4-S-trimers group (G8) were compared. The RBD binding to 534 ACE2 was detected by Alexa 488 conjugated secondary antibody. were assessed by ELISA for antigen-specific IgG antibody titers against S-ecto (b) and RBD (c). 555 ****P < 0.0001. ns, no significance, P > 0.05. d. Serial dilutions of serum from immunized rabbits 556

were assessed for neutralization of live BSL-3 strain SARS-CoV-2 US-WA-1/2020. Neutralization 557 titers were calculated as the reciprocal dilution where infection (cytopathic effect) was reduced by 558 more than 90% relative to infection in the absence of serum. e and f. Comparison of G1 (control 559 phage) and G4 (Ee-NP-S trimer displayed phage) for anti-NP (e) and anti-E (f) IgG antibody titers. 560 ***P < 0.001. 561 562 563 Supplementary Fig. 11 Virus neutralization titers of rabbit sera. Infection of Vero E6 cells by 564

live SARS-CoV-2 US-WA-1/2020 was determined in the presence of rabbit sera at a series of 565 two-fold dilutions starting from 1:4. Culture medium only and CoV-2 virus only were used as 566 negative and positive controls, respectively. R1442 to R1457 refer to tag numbers of rabbits. The 567 data in control groups were presented as means ± SD of 32 wells. The data in rabbit sera groups 568

were shown as means of duplicates. 569 570

We have developed a "universal" vaccine platform centered around bacteriophage T4 572 nanoparticle and CRISPR engineering (Figure 1; Video) . A number of special features 573 demonstrated here would make this a powerful platform to rapidly generate vaccine candidates 574 against any emerging and pandemic pathogen in the future. 575

First, a series of recombinant phages containing SARS-CoV-2 gene insertions were created 576 in days, by CRISPR genome engineering using a combination of type II Cas9 and type V Cpf1 577 nucleases. This combination provided built-in choices for spacers as well as for efficient cleavage 578 of T4 genome that is extensively modified by cytosine hydroxymethylation and glycosylation, to 579 attain near 100% success 21, 22 . 580 Second, a large amount of genetic and structural space available in phage T4 35 was 581 exploited to incorporate payloads containing CoV-2 DNAs, peptides, proteins, and/or complexes 582 into the same nanoparticle. For instance, we have inserted ~6.5 kb full-length spike gene 583 expression cassette, 2.7 kb RBD gene expression cassette, and 1.3 kb nucleocapsid gene into 584 the same genome by replacing nonessential genetic material of T4. It was further expanded by 585

inserting Hoc and Soc fusions, and/or replacing additional nonessential segments that span 586 across the phage genome. In addition, up to 155 copies of a 12-aa Ee peptide and ~100 copies 587 of 433-kDa S-trimers were displayed on the same nanoparticle while ~70 molecules of 50-kDa 588 NP were co-packaged with genome core. These represent unprecedented engineering capability 589 and payload complexity by a vaccine delivery vehicle. 590

Third, different compartments of phage nanostructure were utilized for placing different 591 vaccine cargos. The tips of Hoc fibers with ~170Å reach were used to display short 12-aa Ee 592 peptide epitopes as this would allow efficient capture by antigen presenting cells, and B and T 593 cells 29 . Indeed, these elicited strong antibody titers. At the same time, NP was co-packaged with 594 genome as this mimics NP's natural nucleic acid environment 2, 37 . 595

Fourth, the T4 platform was readily adapted to mammalian-expressed proteins through 596 highly efficient SpyCatcher-SpyTag bridging 39 . This might be essential for proper folding and 597 glycosylation of some pathogen antigens, as in the case of spike trimers 30 . As the Cryo-EM 598 images showed, such spikes anchored to capsid mimic the spikes on SARS-CoV-2 virion 41 599 providing a native-like context for stimulating effective immune responses. 600

Fifth, alternative strategies such as pre-expression from a plasmid and display through 601 subsequent phage infection provided additional advantages to enhance copy number and better 602 control over folding. As demonstrated, this approach yielded 3-6-fold higher copy number of Soc-603

SpyCatcher on phage capsid. However, the hydrophobic RBD remained poorly folded. 604

Sixth, our sequential engineering generated a pipeline of SARS-CoV-2 vaccine candidates 605 in mere weeks, and allowed down-selection of the best vaccine candidate, the phage-decorated 606 trimers, in a single mouse experiment. However, why the DNA-alone vaccines failed to elicit 607 immune responses remains unclear and requires further investigation. 608

Seventh, unlike the DNAs, all the phage-delivered peptides/proteins, whether displayed on 609 surface or packaged inside, generated robust immune responses. The strong virus neutralization 610 titers and ACE-2 blocking titers elicited by T4-delivered trimers in two different animal models, 611 mouse and rabbit, are particularly noteworthy. These responses correlated with protective efficacy 612

where the vaccinated mice were completely protected from acute viral infection. 613

Eighth, T4 nanoparticle vaccines generated balanced TH1 and TH2 derived antibody 614 responses against all three CoV-2 antigens tested. In fact, T4 seems to have a slight TH1-bias. 615

These are desirable properties for protection and distinguish this PAMP-like T4 platform from 616 other subunit vaccine platforms and adjuvant systems 28, 29, 48, 49 . 617

Ninth, the T4 nanoparticle vaccine does not require any adjuvant to stimulate robust anti-618

CoV-2 immune responses, as demonstrated in two animal models. In addition to reducing cost 619 and manufacturing complexity, the adjuvant-less T4 vaccine formulations might provide a safe 620 alternative because reactogenicity to vaccines is often associated with chemical adjuvants used 621 in traditional vaccine formulations. In numerous immunizations with T4 phage, in a variety of 622 animal models including mouse, rat, rabbit, and macaque, no significant adverse reactions were 623 noted 28, 48-50 . 624

Finally, our best T4 vaccine candidate elicited, in addition to spike-specific antibodies, broad 625 antibody responses against two additional virion components, E that is exposed on the surface 626 and NP that is abundantly present on SARS-CoV-2 infected host cells 32, 33 . Furthermore, the 627 spycatcher phage could serve as a "plug-and play" backbone to capture ectodomain trimers from 628 other coronaviruses such as SARS-CoV-1 and MERS 2 , or any spytagged antigen(s) from other 629 infectious agents. Thus, it is conceivable that different vaccine formulations can be "created" at 630 the site of administration by mixing the spycatcher T4 phage with the desired antigen(s) 631

combinations. Co-carrying multiple and distinct antigens in the same formulation increase the 632 breadth of immune responses 51, 52 and since regions of S-ecto, Ee, and NP are conserved in other 633 coronaviruses 1, 2 , the T4 vaccine platform might be considered for expanded protection. 634

In conclusion, we have developed a versatile "universal" nanovaccine design template by 635 which vaccine candidates can be rapidly generated, evaluated in animal models, and transitioned 636 to human clinical trials as is being done currently with the T4-CoV-2 vaccine. As T4 is a highly 637 stable nanoparticle, has good safety profile, and can be manufactured at a relatively low cost, it 638 provides a robust platform to rapidly generate effective vaccines against any epidemic or 639 pandemic pathogen in the future, particularly when multivalent vaccines are essential to protect 640 global communities. accuracy were selected and a few drops of chloroform were added. These plaque-purified "zero 753 stocks" were stored at 4º C. More rounds of CRISPR gene editing were similarly introduced into 754

the same phage as needed as described above. 755

Phage production and purification 756 E. coli strains B40 or B834 were used for the production of amber-phage or non-amber-phage, 757

respectively. Fresh overnight E. coli cells were inoculated in 1 L of Moore's media (20 g tryptone, 758

15 g yeast extract powder, 2 g dextrose, 8 g NaCl, 2 g Na2HPO4, 1 g KH2PO4, dissolved in 1 L 759

MQ water) at 1/50 dilution, and then grown at 37˚C for 2-2.5 hr in a shaker incubator at 200 RPM. 760

When the cells reached a density of ~4 X 10 8 /ml, phages were added at a multiplicity of infection 761

(MOI) of 0.5. The infection mixture was cultured at 37˚C, 200 RPM, for another 2.5 -3 hr and 762

periodically checked under the microscope. As the cells get infected with phage, the shape of 763 cells change from long bacilli to short dumbbell shape. When the cell number started dropping, 764

the culture was transferred to Sorvall GSA bottle and centrifuged at 27, 504 g for 1 hr at 4 ˚C. The 765

supernatant was discarded, and the pellet was resuspended in 50 ml Pi-Mg buffer containing 10 766 µg/ml DNase I (or Benzonase) and one tablet of protease inhibitor cocktail. The resuspended 767 pellet was added with 5 ml chloroform and incubated at 37º C for 1 hr to lyse the bacteria and 768

release the phage. The debris was removed by low-speed centrifugation at 4,302 g for 10 min. 769

The phage-containing supernatant was transferred to a sterile falcon tube and the pellet was 770 discarded. The titer of this phage stock was determined using E. coli B40 or B834. The working 771 stock of phages can be stored at 4˚C for long periods of time with a few drops of chloroform added 772

to prevent microbial contamination, or used as seed phage to make SpyCatcher or Soc-RBD 773 displayed phage, or purified as a vaccine candidate for animal studies. 774

For purification of phage, ~50 ml phage stock was distributed into 5 Corex glass tubes (10 ml 775 each) and sealed with parafilm. The phage stock was centrifuged at 34,540 g for 1 hr using a 776

Sorvall SS34 rotor. The supernatant was discarded and the phage-containing pellet was 777 resuspended with 1-3 ml Pi-Mg buffer plus 5 µl Benzonase overnight at 4˚C. Next, the 778 resuspended phages were loaded onto a CsCl gradient and centrifuged at 152,000 g for 1 hr in a 779

Beckman ultracentrifuge using a SW 55Ti swinging bucket rotor. The purified phage band 780 localized between CsCl densities 1.46 and 1.55 was collected by inserting a syringe right below 781 the phage band and aspirating the band. The phages were dialyzed in high-salt Tris-Mg buffer 782

(10 mM Tris-HCl, pH 7.5, 200 mM NaCl, 5 mM MgCl2) for 4 hr followed by low-salt Tris-Mg buffer 783

(10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 5 mM MgCl2) overnight. The second-round CsCl 784 centrifugation and dialysis of purified phages were applied to obtain purer phages. Two-round-785

CsCl-purified phages were further purified by passing through a 0.22 µm filter to remove any 786 minor bacterial contaminants. The phage concentration and copy numbers of displayed antigens 787

were quantified by 4-20% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). RIPL-Soc-Spycatcher-Amber Suppressor: 50 μg/ml Kanamycin + 37 μg/ml Chloramphenicol + 796 100 μg/ml Ampicillin). The culture was incubated at 37º C, 200 RPM, for 2.5-3 hr. When the cells 797 reached a density of ~4 X 10 8 /ml, 0.5 mM IPTG was added for induction of recombinant protein 798 expression. At 10 min post IPTG addition, the corresponding phages (Hoc-del/Soc-del/IPII-799 del/IPIII-del) were added to infect cells at an MOI of 0.5. The culture was further incubated at 800 37˚C, 200RPM, for 3 hr. The following phage production and purification procedures are the same 801 as described above. 802

Plasmid pCAG-CD5-S-ecto-6P-Spytag was transiently transfected into ExpiCHO cells using 804

ExpiFectamine CHO transfection kit (Thermo Fisher 

In vitro display of S-trimer/rRBD on the T4-SpyCatcher phage was assessed by co-sedimentation 820 as described previously with some modifications 27, 28 . Briefly, two-round CsCl purified and 0.22 821 µm filtered phage particles were sedimented for 45 min at 34,000 g in Protein-LoBind Eppendorf 822

tubes, washed twice with sterilized phosphate-buffered saline (PBS) buffer (pH 7.4), and 823 resuspended in PBS buffer (pH 7.4). S-trimer/rRBD was sedimented for 25 min at 34,000 g to 824 remove any possible aggregates present in the sample. T4-SpyCatcher phages were incubated 825 with S-trimer/rRBD proteins at 4°C for 1 hr. The mixtures were sedimented by centrifugation at 826 34,000 g for 45 min, and unbound protein in the supernatants was removed. After washing twice 827

with excess PBS to further remove the unbound protein and any other minor contaminants, the 828 phage pellets containing the displayed proteins were incubated at 4°C overnight and then 829 resuspended in PBS. For rabbit animal studies, fifty microliters of phage-trimer particles were 830

added to blood agar (TSA with sheep blood) to examine any contamination of a wide variety of 831 fastidious microorganisms. The resuspended pellets were analyzed using Novex 4-20% SDS-832 SDS-PAGE mini gel (Thermo Fisher Scientific, Waltham, MA) to quantify the S trimer/rRBD copies. 833

After Coomassie Blue R-250 (Bio-Rad, CA) staining and destaining, the protein bands on SDS-834 PAGE gels were scanned and quantified by ChemiDoc MP imaging system (BioRad) and image 835 J. The copy numbers of SpyCatcher and displayed S-trimer/rRBD molecules per capsid were 836 calculated using gp23 (major capsid protein; 930 copies) or gp18 (major tail sheath protein; 138 837 copies) as internal controls and S-trimer protein standard. 838

The E.coli expression, denaturation, refolding, and purification of SUMO-RBD-Spy (rRBD) were 840 performed using a similar procedure described previously 53 . Briefly, the BL21-CodonPlus (DE3)-841 RIPL cells containing PET28b-SUMO-RBD-Spy expression plasmid were induced with 0.5 mM 842

isopropyl--D-1-thiogalactopyranoside (IPTG) for 3 h at 28°C. Cells were harvested and 843 resuspended in buffer A (20 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole, 5 mM β-844 mercaptoethanol, pH 7.9) containing protease inhibitor cocktail (Roche, USA, Indianapolis, IN) 845

and Benzonase. After the cells were lysed using a French press (Aminco, Urbana, IL) and 846 centrifuged, the pellet containing the inclusion body proteins was resuspended and washed with 847 buffer B (buffer A + 0.5% Triton X-100). Then, the inclusion bodies were solubilized in buffer C 848 (Buffer A + 8 M urea) by incubating/stirring at 4 °C overnight, followed by centrifugation and 849

clarification. The supernatant containing the denaturing protein was loaded on HisTrap column 850 (AKTA-prime; GE Healthcare) followed by washing with buffer C. The rRBD was refolded on 851

HisTrap column using a linear gradient of 8 to 0 M urea containing buffer D (20 mM Tris-HCl, 500 852 mM NaCl, 5 mM imidazole, 1 mM GSH, 0.1 mM GSSG, 20% glycerol, pH 7.9). Finally, the column 853 was washed with buffer E (20 mM Tris-HCl, 500 mM NaCl, 100 mM imidazole, 20% glycerol, 5% 854 glucose, pH 7.9), and the refolded rRBD was eluted with buffer F (20 mM Tris-HCl, 500 mM NaCl, 855 800 mM imidazole, 20% glycerol, 5% glucose, pH 7.9) and dialyzed to remove imidazole. The 856

proteins were then quantified, aliquoted, and stored at -80°C until use. 857

After treatment with multiple freeze-thaw cycles and Benzonase, phage particles were boiled in 859 SDS loading buffer for 10 min, separated by 4-20% SDS-PAGE, and transferred to nitrocellulose 860 membrane PVDF (Bio-Rad). The PVDF was then blocked with 5% bovine serum albumin (BSA)-861 PBS (pH 7.4) buffer at RT for 1 hr with gentle shaking. Anti-NP or anti-RBD primary antibodies 862

were added to the blots and incubated overnight at 4°C in PBS-5% BSA, followed by five times 863 rinsing in PBST buffer [1×PBS (pH 7.4) and 0.05% Tween 20]. Goat-anti-mouse or goat-anti-864 rabbit HRP-conjugated antibody (Thermo Fisher) was applied at a 1:5000 dilution in 5% BSA-865

PBST for 1 hr at RT with gentle shaking. After rinsing five times in PBST, binding was visualized 866

with an enhanced chemiluminescence substrate (Bio-Rad) using the Bio-Rad Gel Doc XR+ 867

System and Image Lab software according to the manufacturer's instructions (Bio-Rad). 868

HEK293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco) 870

supplemented with 1% antibiotics (Thermo Fisher), 1x HEPES (Thermo Fisher), and 10% fetal 871 bovine serum (Thermo Fisher). Cells were passaged with 0.25% (w/v) trypsin/0.53 mM EDTA at 872 a sub-cultivation ratio of 1:5 at 80 to 90% confluence. Cultures were incubated in a humidified 873

atmosphere at 37°C and 5% CO2. The recombinant plasmid containing human ACE2 gene 874 (Addgene #1786) was transfected into HEK293T cells using Lipofectamine 2000 Transfection 875

Reagent (Thermo Fisher) according to the manufacturer's instructions. Two days after ACE2 876 plasmid transfection, the cells were used for RBD or phage binding assay. 877

Human ACE2 transfected HEK293T cells were washed with PBS twice and then fixed with 4% 879 formaldehyde for 15 min at RT. After rinsing twice in PBS for 5 min each, cells were blocked in 880

blocking buffer (5% BSA-PBS) for 1 hr at RT. Recombinant SARS-CoV-2 RBD protein (Sino 881

Biological) was added to the cells to a final concentration of 0.2 µg/ml in the presence or absence 882

of the sera with a series of dilutions. The unbound RBD was removed by washing cells five times 883

with PBST (PBS + 0.1% Tween 20) for 5 min each. The 1/1000 diluted human anti-RBD 884 monoclonal antibody (Thermo Fisher) was added to cells and incubated in a humidified chamber 885

for 1 hr at RT or overnight at 4°C. After rinsing five times in PBST for 5 min each, Alexa488-or 886

Rhodamine-conjugated goat anti-human secondary antibody was added (1/500 dilution) (Thermo 887

Fisher), and incubated for 2~3 hr at room temperature in the dark. The cells were then rinsed five 888 times in PBST for 5 min each and counter-stained with 1 μg/ml Hoechst 33342 (Thermo Fisher) 889

for 5 min. The fluorescent signals were recorded by fluorescence microscopy (Carl Zeiss). 890

Binding of T4-S trimer-GFP phages to cell surface ACE2 891

Soc-GFP protein was produced as described previously 27 . In vitro display of Soc-GFP on the T4-892

SpyCatcher or T4-S trimer phage was assessed by the co-sedimentation and SDS-PAGE, similar 893

to the procedures of S-trimers displayed on T4 phage. The T4-SpyCatcher-GFP or T4-S trimer-894 GFP phages were resuspended in Opti-MEM medium (Thermo Fisher) and then added to ACE2-895 transfected HEK293T cells. After 6 hr incubation, the unbound phages were removed by rinsing 896 three times in PBS for 5 min each. The GFP fluorescence was recorded by fluorescence 897 microscopy (Carl Zeiss). 898

We followed the recommendations of the National Institutes of Health about mouse study (the 900

Guide for the Care and Use of Laboratory Animals Six-to eight-week-old female BALB/c mice (The Jackson Laboratory) were randomly grouped 907

(5 mice per group) and allowed to acclimate for 14 days. The phage vaccine candidates were 908 administered by intramuscular (i.m.) injections into their hind legs. A total of 6 ×10 11 phages 909

carrying approximately 20 µg of SARS-CoV-2 antigen(s) were injected on days 0 (prime), 21 910

(boost 1), and 42 (boost 2). Negative control mice received the same volume of PBS buffer (Naive) 911

or the same amount of T4 control phage. A group of mice immunized with purified S trimer (20 912 μg) adjuvanted with Alhydrogel was included as the positive control. Blood was drawn from each 913 animal on days 0 (pre-bleed), 14, 35, and 56, and the isolated sera were stored at −80°C. 914

All experiments were performed at Envigo/Cocalico Biologicals (Reamstown, PA) in accordance 916 with institutional guidelines. Adult New Zealand White rabbits were immunized intramuscularly in 917 the flank region with 3X10 11 PFU T4 phages/dose in 0.2 mL saline (n = 4 for group). Pre-immune 918

test-bleeds were first obtained via venipuncture of the marginal vein of the ear on Day 1. Animals 919

were immunized on Days 1, and 15 (Prime + One-boost regimen). Immune sera were obtained 920 on Day 25. 921

ELISA plates (Evergreen Scientific) were coated with 100 μl per well of 1 μg/ml of SARS-CoV-2 923

S-ecto protein (Sino Biological), SARS-CoV-2 RBD-untagged protein (Sino Biological), SARS-924

CoV-2 NP protein (Sino Biological), or SARS-CoV-2 E protein (1-75 aa) (Thermo Fisher) in 925

coating buffer [0.05 M sodium carbonate-sodium bicarbonate (pH 9.6)]. After overnight incubation 926 at 4°C, the plates were washed twice with PBS buffer and blocked for 2 hr at 37°C with 200 μl per 927

well PBS-5% BSA buffer. Serum samples were diluted with a 5-fold dilution series beginning with 928 an initial 100-fold dilution in PBS-1% BSA. One hundred microliters of diluted serum samples 929

were added to each well and the plates were incubated at 37°C for 1 hr. After washing five times 930

with PBST (PBS + 0.05% Tween-20), the secondary antibody was added at 1:10,000 dilution in 931 

703 were constructed by two rounds of cloning. First, the multiple cloning site (MCS) (NcoI, NdeI, NheI, 704 and BmtI)-linker (4GGS)-Soc-linker (2GGGGS)-MCS (HindIII, EagI, NotI, and XhoI) was amplified 705 using Soc-plasmid template and cloned into the pET28b DNA linearized with NcoI and XhoI 706 restriction enzymes to generate pET28b

RBDs were amplified and inserted to 3'-or 5'-MCS of 708 pET28b-MCS-L-Soc-L-MCS as needed. CTS-NP and Ee-Hoc expression fragments were 709 amplified using synthesized NP and T4 genomic DNA respectively, and cloned into NcoI and 710 XhoI-linearized pET28b

were constructed using standard 713 protocols. The RBD fragment was amplified using the WT spike gene, and CD5 secretion leading 714 peptide (MPMGSLQPLATLYLLGMLVASVLA) was added to the N terminus of RBD by PCR. The 715 CD5-RBD was directionally cloned into pAAV vector (Cell Biolabs) using the HindIII and XhoI 716 restriction enzyme sites (pCMV-CD5-RBD). For the construction of pCAG-CD5-S-fl, pCAG-CD5-717 S-ecto-6P, and pCAG-CD5-S-ecto-6P-Spytag, plasmids pCAG-S-fl and pCAG-S-ecto-6P were 718 used as template and backbone. The CD5 fragment was cloned into N terminus of S-fl or S-ecto-719 6P using KpnI and EcoRI restriction sites. Similarly, Spytag (RGVPHIVMVDAYKRYK) was cloned 720 into the C terminus of S-ecto using BamHI and XhoI restriction sites

were 727 mixed with 350 μl of spacer-containing E. coli (~10 8 cells/ml). E. coli cells without spacer were 728 used as a control. After incubation at 37°C for 7 min, 3.5 ml of 0.75% top agar with spectinomycin 729 (50 μg/mL) was added to each tube, mixed, and poured onto LB plate. The plates were incubated 730 at 37°C overnight to allow the formation of plaques

CRISPR-mediated phage T4 genome editing and recombination

either B834/P301 without amber suppressor, or B40/RIPL with 736 amber suppressor. E.coli cells transformed with single plasmids, either the donor plasmid or the 737 CRISPR spacer plasmid, were used as controls. An appropriate amount of T4 phages, as 738 determined by the EOP as described above, were added to E. coli and incubated for 7 min at 739 37º C. After adding 3.5 ml of 0.75% top agar containing 50 μg/ml spectinomycin and 50 μg/ml 740 kanamycin, the infection mixture was poured onto LB plate and incubated overnight

μl per well) using either goat-anti-mouse IgG-HRP

goat-anti-mouse IgG2a-HRP (Thermo Fisher), or goat-anti-rabbit IgG-HRP (Abcam)

After 5-935 10 min, the enzymatic reaction was stopped by adding TMB BlueSTOP (KPL) solution. The 936 absorbance was read within 30 min at 650 nm on a VersaMax spectrophotometer. The endpoint 937 titer was defined as the highest reciprocal dilution of serum

Binding of T4 displayed RBD or S-trimer to human ACE2 protein

T4 displayed RBD/S-trimer to 941 human ACE2 protein was performed as described above. Briefly, 100 ng protein or 1×10 10 phages 942 were coated on plates overnight at 4°C. After blocking with PBS-5% BSA buffer, recombinant 943 human ACE2-mouse Fc protein (Sino Biological) with a series of dilution was added and 944 incubated for 1 hr at 37°C. Plates were then incubated with the secondary goat-anti-mouse IgG-945 HRP antibody and developed with TMB substrate

Virus Neutralization assay using BSL-3 live SARS-CoV-2

After incubation under BSL-953 3 conditions, 100 µl of the mixtures in individual wells were transferred to Vero E6 cell monolayer 954 grown in 96-well microtiter plates that containing 100 µl of MEM/2%FCS medium in each well and 955 were cultured for 72 h at 37°C before assessing the presence or absence of cytopathic effect 956 (CPE)

were first 962 decomplemented at 56°C for 60 min, and were then serially diluted in 384 well plates, in duplicate, 963 using a BioTek Precision 2000 liquid handler, along with two reference sera. Twenty microliter 964 aliquots of SARS-CoV-2_USA-WA1/2020 were added to all test wells and positive control wells 965 to yield a final MOI of 10 under BSL-3 conditions. Vero (ATCC® CCL-81) cells were maintained 966 in a high-glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal 967 bovine serum (FBS; HyClone Laboratories, South Logan, UT) and 1% penicillin/streptomycin at 968 37°C with 5% CO2. After preincubating the plates for 1 hr, 20 μl of Vero cells (10 6 /ml), containing 969 50 µg/mL of propidium iodide (PI), was added to all wells using the liquid handler

Longitudinal image acquisition and processing for virus-induced cytopathic effect (CPE) 972 and cell death (PI uptake) were performed every six hrs, until cell death profiles had crested and 973 stabilized (3.5 days). Neutralizing antibody titers (expressed as IC50 or IC90) were obtained from 974 four-parameter logistic curve-fits of cell death profiles using OriginPro 9

Challenge of the mice with mouse-adapted live BSL-3 SARS-CoV-2 virus

A new coronavirus associated with human respiratory disease in China

Coronavirus biology and replication: 997 implications for SARS-CoV-2

COVID-19 vaccine development and a potential nanomaterial path forward. Nat. 1000 Nanotechnol

SARS-CoV-2 vaccines in development

Learning from the past: development of safe and effective COVID-19 1003 vaccines

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen 1005 preparedness

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective 1007 immunity

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 1009 (AZD1222) vaccine in a phase 1/2 clinical trial

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-1011 2 spike protein receptor-binding domain induces potent neutralising antibody responses

Immune-mediated approaches against COVID-19

Structure and function of bacteriophage T4

Cryo-EM structure of the bacteriophage T4 isometric head at 3.3-A resolution and 1020 its relevance to the assembly of icosahedral viruses

Molecular architecture of the prolate head of bacteriophage T4

The two dispensable structural proteins (soc and hoc) of the T4 phage 1024 capsid; their purification and properties, isolation and characterization of the defective mutants, 1025 and their binding with the defective heads in vitro

Structure of the small outer capsid 1027 protein, Soc: a clamp for stabilizing capsids of T4-like phages

Structure of the three N-terminal immunoglobulin domains of the highly 1029 immunogenic outer capsid protein from a T4-like bacteriophage

Bacteriophage adhering to mucus provide a non-host-derived immunity

Engineering of Bacteriophage T4 Genome Using 1033 CRISPR-Cas9

Covalent modifications of bacteriophage genome confer a degree of resistance to 1035 bacterial CRISPR systems

Structural morphing in a symmetry-mismatched viral vertex

The structure of the phage T4 DNA packaging motor suggests a mechanism 1039 dependent on electrostatic forces

Assembly of the small outer capsid protein, Soc, 1041 on bacteriophage T4: a novel system for high density display of multiple large anthrax toxins and 1042 foreign proteins on phage capsid

In vitro binding of anthrax protective antigen on bacteriophage T4 capsid 1044 surface through Hoc-capsid interactions: a strategy for efficient display of large full-length 1045 proteins

In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA 1047 packaging machine

A prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and 1049 proteins into human cells

Bacteriophage T4 nanoparticles for vaccine 1051 delivery against infectious diseases

Veesler Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Structural insight into the role of novel SARS-CoV-2 E protein: A potential 1057 target for vaccine development and other therapeutic strategies

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and 1059 uninfected controls

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 1061 receptor

From Host to Phage Metabolism: Hot Tales of Phage T4's Takeover of E. coli

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 1065 Disease and Unexposed Individuals

Biochemical characterization of SARS-CoV-2 nucleocapsid protein

Capsid targeting sequence targets foreign proteins into 1069 bacteriophage T4 and permits proteolytic processing

Approaching infinite affinity through engineering of peptide-protein interaction

Proc. Natl. Acad. Sci

Expression and purification of SARS coronavirus proteins using SUMO-fusions

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike 1077 Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

A double-inactivated severe acute respiratory syndrome coronavirus vaccine 1082 provides incomplete protection in mice and induces increased eosinophilic proinflammatory 1083 pulmonary response upon challenge

Promotion of B cell immune 1085 responses via an alum-induced myeloid cell population

Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient

A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard 1089 Laboratory Mice

A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague

Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia 1093 pestis as next generation plague vaccines

Highly effective generic adjuvant systems for orphan or poverty-related vaccines

New Vaccine Design and Delivery Technologies

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein 1099 Nanoparticle Vaccines for SARS-CoV-2

Prokaryotic expression, refolding, and purification of 1101 fragment 450-650 of the spike protein of SARS-coronavirus

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and 1103 immunization interval protects human transgenic mice from MERS-CoV infection. Hum. Vaccines 1104 Immunother

generous gift from Ralph Baric at UNC, by the intranasal route as previously described 54 . Briefly, 979 mice were inoculated with 60 µl of SARS-CoV2-MA10 at a dose of ~10 5 TCID50. The animals 980were weighed every day over the indicated period of time for monitoring the onset of morbidity 981(weight loss and other signs of illness) and mortality, as the endpoints for evaluating the vaccine 982 efficacy. 983

All the data were presented as means ± SEM except where indicated. Statistical analyses were 985 performed by Graph Pad Prism 9.0 software using one-way or two-way Analysis of variance 986(ANOVA) according to the data. Tukey's multiple comparisons post-test was used to compare 987 individual groups. Significant differences between two groups were indicated by *P < 0.05, **P < 988 0.01, ***P < 0.001, and ****P < 0.0001. ns, no significance. P-values of < 0.05 were considered 989 significant.